Tozasertib

Name: Tozasertib
SKU: T5996
Availability: InStock

Product ID T5996

Cas No. 639089-54-6

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

Tozasertib is an anticancer chemotherapeutic pan-aurora kinase (AurK) inhibitor that also inhibits FMS-like tyrosine kinase 3 (FLT3) and Abl. Tozasertib is currently in clinical trials as a potential treatment for acute lymphoblastic leukemia (ALL). In cellular models of cancer, tozasertib activates caspase-3 and PARP and decreases expression of HDAC, increasing apoptosis and inhibiting cell growth. In other cellular models, tozasertib inhibits cell proliferation and metastasis by blocking downstream ERK signaling and downregulating cdc25c and cyclin B. This compound also decreases tumor growth in an in vivo model of prostate cancer.

Product Info

Cas No.	639089-54-6
Purity	≥98%
Formula	C₂₃H₂₈N₈O_S
Formula Wt.	464.59
Chemical Name	N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
IUPAC Name	N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
Synonym	VX680, MK0457
Melting Point	245-260°C
Solubility	DMSO at 100 mg/mL
Appearance	White to pale yellow powder

Shipping and Storage

Store Temp	Ambient
Ship Temp	Ambient

Downloads

MSDS	T5996 MSDS PDF
Info Sheet	T5996 Info Sheet PDF

References

Okabe S, Tauchi T, Tanaka Y, et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013 Apr 4;13(1):32. PMID: 23556431.

Li Y, Zhou W, Wei L, et al. The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol. 2012 Dec;41(6):2139-49. PMID: 23007526.

Giles FJ, Swords RT, Nagler A, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7. PMID: 22772060.

Jeet V, Russell PJ, Verma ND, et al. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets. 2012 Feb;12(2):144-63. PMID: 22229247.

Salah E, Ugochukwu E, Barr AJ, et al. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J Med Chem. 2011 Apr 14;54(7):2359-67. PMID: 21417343.

Oliveira TM, Ahmad R, Engh RA. VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. J Phys Chem A. 2011 Apr 28;115(16):3895-904. PMID: 21306143.

Custom Order

Name*
First Last
Company/Institution
Email*
Enter Email Confirm Email
Product ID
Product Name
Unit Size
Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
Unit Label
Quantity
Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
Comments
Name
This field is for validation purposes and should be left unchanged.

Tozasertib

Quicklinks

Description

Product Info

Shipping and Storage

Downloads

References

Custom Order

Related Products

Metyrapone

Nimorazole

Mycophenolate Mofetil

Recombinant Multi-epitope Chimeric HIV Antigen 1

Flupirtine Maleate

2,3,5,6-Tetramethylpyrazine

Baclofen

Exendin-3

Methotrexate Hydrate

Neuromedin U, rat

Growth Hormone Releasing Factor, sheep

H89

Rosiglitazone

Trimebutine Maleate

NVP-BHG712

Verapamil Hydrochloride

Ginkgolide B

RDEA119

Antimycin A

S-Methyl-L-cysteine

Footer